Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer
Latest Information Update: 09 Jun 2020
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms Recover HER2
- 07 Jun 2020 Status changed from recruiting to discontinued.
- 06 Dec 2015 Status changed from not yet recruiting to recruiting, , according to University Hospital Medical Information Network - Japan record.
- 14 Jul 2014 New trial record